Purpose: Neuroendocrine tumours (NETs) can be imaged with scintigraphy using radiolabelled somatostatin analogues. The aim of our study was to compare the value of (68)Ga-DOTATOC PET and (111)In-DTPAOC SPECT (Octreoscan) in the detection of NET manifestations.

Methods: Twenty-seven NET patients were prospectively examined. (68)Ga-DOTATOC PET and (111)In-DTPAOC SPECT were performed using standard techniques. Treatment was not applied in between. Mean and maximum standardised uptake values (SUVs) were calculated for PET findings. Tumour/non-tumour ratios were calculated for SPECT findings. Findings were compared by a region-by-region analysis and verified with histopathology, CT and MRI within 21 days.

Results: SUVs of positive lesions on (68)Ga-DOTATOC PET ranged from 0.7 to 29.3 (mean SUV) and from 0.9 to 34.4 (maximum SUV). Tumour/non-tumour ratios on (111)In-DTPAOC SPECT ranged from 1.8 to 7.3. In imaging lung and skeletal manifestations, (68)Ga-DOTATOC PET was more efficient than (111)In-DTPAOC SPECT. All discrepant lung findings and 77.8% of discrepant osseous findings were verified as true positive PET interpretations. In regional comparison of liver and brain, (68)Ga-DOTATOC PET and (111)In-DTPAOC SPECT were identical. In lymph nodes, the pancreas and the gastro-intestinal system, different values of the two techniques were not indicated in regional analyses. In a single patient, surgical interventions were changed on the basis of (68)Ga-DOTATOC PET findings.

Conclusion: (68)Ga-DOTATOC PET is superior to (111)In-DTPAOC SPECT in the detection of NET manifestations in the lung and skeleton and similar for the detection of NET manifestations in the liver and brain. (68)Ga-DOTATOC PET is advantageous in guiding the clinical management.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-007-0450-1DOI Listing

Publication Analysis

Top Keywords

68ga-dotatoc pet
36
111in-dtpaoc spect
24
pet 111in-dtpaoc
16
detection net
12
pet
11
spect
8
neuroendocrine tumours
8
68ga-dotatoc
8
tumour/non-tumour ratios
8
liver brain
8

Similar Publications

Tumor-induced osteomalacia is characterized by hypophosphatemia and fragility fractures caused by fibroblast growth factor 23 (FGF23)-producing tumors. We report a case of tumor-induced osteomalacia in which the tumor location could be determined by gallium 68 (Ga)-DOTATOC positron emission tomography (PET)/computed tomography (CT). A 74-year-old woman had recurrent fractures and bone pain.

View Article and Find Full Text PDF

Gallium-68-DOTA-D-phe1-try3-octreotide (Ga-DOTATOC) positron emission tomography/computed tomography (PET/CT) is a crucial diagnostic tool for neuroendocrine tumors (NET). Its accuracy is influenced by radiochemical purity and patient preparation. We present two cases where unexpected radiotracer uptake in Ga-DOTATOC PET/CT imaging was observed.

View Article and Find Full Text PDF

Purpose: To evaluate organ-specific response to [Lu]DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) in patients with small intestine neuroendocrine tumor (SiNET) through [Ga]DOTATOC PET/CT, and to analyze tumor uptake and functional volume variations at different metastatic sites in relation to disease progression during clinical follow-up after treatment.

Methods: A retrospective analysis was conducted on 33 metastatic patients. PET/CT were performed pre-treatment (PET0), mid-treatment after two PRRT cycles (PET2), and post-treatment (PET4).

View Article and Find Full Text PDF

Ga-DOTATOC PET/CT is a functional imaging modality that has revolutionized the evaluation of well-differentiated neuroendocrine tumors (NETs) by targeting somatostatin receptors. This technique has largely replaced conventional gamma camera imaging with 111In-labeled octreotide due to its superior sensitivity and resolution. While the physiologic distribution, normal variations, and common pitfalls associated with Ga-DOTATOC imaging are well documented, rare but clinically significant pitfalls can still occur.

View Article and Find Full Text PDF

Ectopic adrenocorticotrophic hormone syndrome in a 10-year-old girl with a thymic neuroendocrine tumor: a case report.

BMC Endocr Disord

November 2024

Developmental Endocrinology, Metabolism, Genetics and Endocrine Oncology Affinity Group, Eunice Kennedy Shriver NICHD, NIH, Bethesda, MD, USA.

Background: Thymic neuroendocrine tumor as a cause of Cushing syndrome is extremely rare in children.

Case Presentation: We report a case of a 10-year-old girl who presented with typical symptoms and signs of hypercortisolemia, including bone fractures, growth retardation, and kidney stones. The patient was managed with oral ketoconazole, during which she experienced adrenal insufficiency, possibly due to either cyclic adrenocorticotropic hormone (ACTH) secretion or concurrent COVID-19 infection.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!